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Section A 
Short Answer Questions 
Total No of Marks for this section:  100 
This section should be answered in the Answer Booklet provided. 
Marks for each question are indicated.  Suggested Time allocation for Section B:  180 mins 
___________________________ 
 
 Question 1. Drug development process and methods 
(a) As chief scientific officer of a medium sized biopharma company specialising in oncology, 
you have been asked for you opinion on whether your company should buy the intellectual 
property relating to a new anti-bacterial chemotherapeutic from a university start-up. The 
project is targeting what is believed to be a novel mechanism for disrupting cell wall synthesis. 
The project has progressed to the stage of having several hits in a biophysical screening 
campaign.  
What information would you expect the start-up to provide as part of the IP? Produce an 
annotated schematic that you could use as part of your briefing to the company board 
explaining the benefits and risks associated with taking on this project. Assume that the 
annotations need to be sufficient for the schematic to be understood without you being 
present to explain it. 
 
This presentation should include a short discussion of cell wall growth inhibition 
(Marks 10) 
(b) Tropical diseases affect more than 1 billion people, mostly in developing regions of the 
world.  
i.  Give 2 examples of tropical diseases.  
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Question 2. Metabolomics and natural regulators 
(a) Give examples of and explain the function of medicinal chemistry modifications to drug 
molecules that give rise to changes in their metabolic handling, compare and contrast this with 
the structural and chemical properties of natural regulators and explain the reasons why 
modifications to this class of lead compounds are required to make a marketable drug 
 
 (Marks 10) 
(b) In one sentence define the following terms: 
i. Metabolomics 
ii. Lipidomics 
iii. Metabolic footprinting 
 (Marks 3) 
(c) Using a flowchart, outline the key steps in the metabolomics analysis (profiling) of tissue 
extracts taken from a study of 50 individuals. Include details on sample preparation and the 
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Question 3. Hit-to-lead chemistry 
(a) Define: 
i. Rational drug design 
ii. Hanchz’s rule 
iii. CLog P 
iv. The “rule of three” (2 marks) 
(Marks 5) 
(b) Tricyclic moieties are common in drug molecule. However, the specific shape 
(conformation) of the molecule can be manipulated by changing the atoms in the 
central ring. What changes would need to be made to the atoms in the central ring of 
the following compound (a xanthylium salt) to effect the overall shape of the molecule. 
 
 
 (Marks 8) 
(c) The compound below was discovered to be an effective enzyme inhibitor. What 
modifications would you make to this compound in order to discover the pharmacophore and 
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Question 4. Screening and structure based design 
(a) Define: 
i. High information content screen 
ii. Agonist 




i. In the diagram below, what type of reaction is occurring?  
Using the concept of bioisosteres: 
ii. Design a reversible competitive inhibitor for the following reaction. Explain your reasoning 
iii. Design a multi-substrate analogue inhibitor. Explain your reasoning 
  
(Marks 7) 
(c) Surface plasmon resonance, isothermal titration calorimetry and nuclear magnetic 
resonance are all common biophysical methods for screening compound libraries for binding to 
isolated target molecules.  
In terms of structural information gathered, binding kinetics and thermodynamics, explain the 
relative advantages of these three techniques for screening a pharmaceutical compound 
library for binding to a soluble protein target.  
(Marks 9) 
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Question 5. Target interaction chemistry and oncology agents 
(a)  Describe how you would use the medicinal chemistry techniques of producing 
homologous series and/or the introduction of bio-isosteres into a chain to change the 
potency and selectivity of a drug designed to interact with an active site on a 






i. Draw, annotate and explain the organic chemical reaction mechanism for the 
interaction between the alkylating cytotoxic cancer chemotherapeutic 
cyclophosphamide (structure below) and DNA. Explain briefly why and how this 




ii. Compare and contrast the DNA interaction of alkylating and intercalating agents 
                                                                
(Marks 8) 
(c)  Explain one aspect of medicinal chemistry that is not covered anywhere else in this 
exam paper 
  
(Marks 4) 
 
 
